Recently, there has been pertinent share price performance divergence between Novartis and Roche. While, for a long time, Novartis had the upper hand, it seems that Roche’s (rare) underperformance offers a window of opportunity. Remember, despite the recent concerns, some of which are/have also moderating/moderated, Roche still remains the undisputed leader on a host of performance parameters.
